You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.
Noridian GBA has issued the LCD for use of the Decipher Prostate Biopsy genomic classifier in patients with very low and low-risk prostate cancer.
Palmetto proposes to cover the assay for prostate cancer patients who are at very low and low risk of negative outcomes with active surveillance by NCCN guidelines.
Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.
GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.
GenomeDx will have exclusive rights to distribute the molecular tests in most of the US, while Pathnostics continues to perform the assays in-house.
The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.